pentamidine has been researched along with Leishmaniasis, Cutaneous in 69 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report 2 patients who developed pentamidine-induced rhabdomyolysis during treatment of leishmaniasis." | 7.71 | [Rhabdomyolysis induced by pentamidine (Pentacarinat) during treatment of cutaneous leishmaniasis: 2 cases]. ( Heid, E; Lieber-Mbomeyo, A; Lipsker, D; Miléa, M, 2002) |
| "We report 2 patients who developed pentamidine-induced rhabdomyolysis during treatment of leishmaniasis." | 3.71 | [Rhabdomyolysis induced by pentamidine (Pentacarinat) during treatment of cutaneous leishmaniasis: 2 cases]. ( Heid, E; Lieber-Mbomeyo, A; Lipsker, D; Miléa, M, 2002) |
| "Pentamidine was initially used as metanolsulfonate or mesylate (Lomidine) at a dose of 4 mg/kg/daily, containing 2." | 2.87 | An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. ( Allan Villa Rouco da Silva, G; Chrusciak Talhari Cortez, C; Chrusciak Talhari, A; da Costa Oliveira, B; de Oliveira Guerra, JA; Gabrielle Ramos de Mesquita, T; Gadelha, EPN; Morais Rocha, N; Ramasawmy, R, 2018) |
| "IL pentamidine is an attractive alternative to ILSb on the basis of efficacy for Bolivian L." | 2.82 | Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis. ( Berman, J; Paz, D; Quispe, J; Rivero, D; Soto, J; Soto, P; Toledo, J, 2016) |
| "Standard treatment of cutaneous leishmaniasis (CL) in Suriname entails three injections of pentamidine isethionate (PI) 4 mg/kg per injection in 7 days (7 day regimen)." | 2.80 | Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname. ( de Vries, HJ; Fat, RF; Hu, RV; Kent, AD; Sabajo, LO; Straetemans, M, 2015) |
| " Severe and irreversible adverse effect appear to be rare." | 2.72 | Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review. ( Bartoloni, A; Lagi, F; Piccica, M; Zammarchi, L, 2021) |
| "Pentamidine was compared with meglumine antimoniate (Glucantime) for 80 patients with cutaneous leishmaniasis due to Leishmania braziliensis in Peru." | 2.71 | Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. ( Andersen, EM; Berman, JD; Colina, O; Cruz-Saldarriaga, M; Echevarria, J; Llanos-Cuentas, A; Luz-Cjuno, M; Miranda-Verastegui, C, 2005) |
| "Pentamidine isethionate is a safe and effective first-line treatment for Old World leishmaniasis." | 2.69 | Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. ( Dedet, JP; Dereure, O; Guilhou, JJ; Guillot, B; Hellier, I; Pratlong, F; Tournillac, I, 2000) |
| " The objective of this review was to identify and classify the main adverse effects associated with these drugs and to estimate the frequency of these effects, whenever possible." | 2.47 | Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. ( Andrade, CA; Martins, MM; Marzochi, MC; Oliveira, LF; Oliveira, RV; Passos, SL; Schubach, AO, 2011) |
| "We report a 46-year-old patient with acquired immune deficiency syndrome who, 7 months after diagnosis of VL, developed PKDL and uveal leishmaniasis following HAART-induced immune recovery." | 2.44 | Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. ( Acquaviva, V; Antinori, S; Bestetti, G; Corbellino, M; Foschi, A; Longhi, E; Meroni, L; Parravicini, C; Piolini, R; Trovati, S, 2007) |
| "Pentamidine was radioiodinated with (131)I." | 1.40 | Evaluation of (131)I-pentamidine for scintigraphy of experimentally Leishmania tropica-infected hamsters. ( Bekiş, R; Er, Ö; Eren, MŞ; Girginkardeşler, N; Inceboz, T; Lambrecht, FY; Özbilgin, A; Yilmaz, O, 2014) |
| "Old World cutaneous leishmaniasis is caused by infection with Leishmania major and Leishmania tropica." | 1.35 | Inhibition by Dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis. ( Boykin, DW; Hall, JE; Kumar, A; Rosypal, AC; Salem, M; Stephens, CE; Tidwell, RR; Werbovetz, KA, 2008) |
| "Extensive rhabdomyolysis was observed in all cases tested: this side-effect has not been reported." | 1.32 | [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate]. ( Banzet, S; Boutin, JP; Chaudier, B; Chouc, C; Dampierre, H; Garnotel, E; Hovette, P; Kraemer, P; Lepage, J; Lightburn, E; Meynard, JB; Morand, JJ; Morillon, M; Pages, F; Patte, JH, 2003) |
| "Disseminated cutaneous leishmaniasis is characterized by the presence of a large (> or =10) number of lesions at several anatomic sites (head, limbs, and trunk)." | 1.32 | Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. ( Carme, B; Clyti, E; Couppié, P; Dedet, JP; Pradinaud, R; Sainte-Marie, D, 2004) |
| "Pentamidine mesylate was introduced by Niemel in 1973 for the treatment of cutaneous leishmaniasis in Surinam." | 1.31 | Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. ( Lai A Fat, EJ; Lai A Fat, RF; Soetosenojo, RM; Vrede, MA, 2002) |
| "Recurrence was observed in two patients who were retreated using the same agent." | 1.31 | [Epidemics of cutaneous leishmaniasis in military personnel working in French Guiana]. ( Banzet, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.45) | 18.7374 |
| 1990's | 9 (13.04) | 18.2507 |
| 2000's | 31 (44.93) | 29.6817 |
| 2010's | 16 (23.19) | 24.3611 |
| 2020's | 12 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Henry, K | 1 |
| Mayet, A | 1 |
| Hernandez, M | 2 |
| Frechard, G | 1 |
| Blanc, PA | 1 |
| Schmitt, M | 1 |
| André, N | 1 |
| Loreau, JM | 1 |
| Ginouves, M | 2 |
| Prévot, G | 3 |
| Couppié, P | 11 |
| Demar, M | 3 |
| Blaizot, R | 2 |
| Salazar-Villamizar, ME | 1 |
| Escobar, P | 2 |
| Bano, S | 3 |
| Bibi, M | 3 |
| Farooq, S | 3 |
| Zafar, H | 3 |
| Shaikh, M | 3 |
| Khoso, BK | 3 |
| Yousuf, S | 3 |
| Choudhary, MI | 3 |
| Castro, MDM | 2 |
| Rode, J | 1 |
| Machado, PRL | 1 |
| Llanos-Cuentas, A | 2 |
| Hueb, M | 1 |
| Cota, G | 1 |
| Rojas, IV | 1 |
| Orobio, Y | 1 |
| Oviedo Sarmiento, O | 1 |
| Rojas, E | 1 |
| Quintero, J | 1 |
| Pimentel, MIF | 1 |
| Soto, J | 4 |
| Suprien, C | 1 |
| Alvarez, F | 1 |
| Ramos, AP | 1 |
| Arantes, RBDS | 1 |
| da Silva, RE | 1 |
| Arenas, CM | 1 |
| Vélez, ID | 1 |
| Lyra, MR | 1 |
| Saravia, NG | 1 |
| Arana, B | 1 |
| Alexander, N | 1 |
| Anjum, A | 1 |
| Shabbir, K | 1 |
| Din, FU | 1 |
| Shafique, S | 1 |
| Zaidi, SS | 1 |
| Almari, AH | 1 |
| Alqahtani, T | 1 |
| Maryiam, A | 1 |
| Moneeb Khan, M | 1 |
| Al Fatease, A | 1 |
| Bashir, S | 1 |
| Khan, GM | 1 |
| Heleine, M | 1 |
| Elenga, N | 1 |
| Njuieyon, F | 1 |
| Martin, E | 1 |
| Piat, C | 1 |
| Pansart, C | 1 |
| Pennini, SN | 1 |
| de Oliveira Guerra, JA | 2 |
| Rebello, PFB | 1 |
| Abtibol-Bernardino, MR | 1 |
| de Castro, LL | 1 |
| da Silva Balieiro, AA | 1 |
| de Oliveira Ferreira, C | 1 |
| Noronha, AB | 1 |
| Dos Santos da Silva, CG | 1 |
| Leturiondo, AL | 1 |
| Vital de Jesus, D | 1 |
| de Araújo Santos, FJ | 1 |
| Chrusciak-Talhari, A | 1 |
| Guerra, MDGVB | 2 |
| Talhari, S | 1 |
| Simon, S | 1 |
| Bourreau, E | 3 |
| Rogier, S | 1 |
| Brousse, P | 1 |
| Travers, P | 1 |
| Pommier de Santi, V | 1 |
| Briolant, S | 1 |
| Cardoso Santos, C | 1 |
| Meuser Batista, M | 1 |
| Inam Ullah, A | 1 |
| Rama Krishna Reddy, T | 1 |
| Soeiro, MNC | 1 |
| Correa-Cárdenas, CA | 1 |
| Pérez, J | 1 |
| Patino, LH | 1 |
| Ramírez, JD | 1 |
| Duque, MC | 1 |
| Romero, Y | 1 |
| Cantillo-Barraza, O | 1 |
| Rodríguez, O | 1 |
| Alvarado, MT | 1 |
| Cruz, C | 1 |
| Méndez, C | 1 |
| Petruccelli, KC | 1 |
| Couceiro, KN | 1 |
| Vasconcelos, ZS | 1 |
| Brandão, ARJ | 1 |
| Silva, MHSE | 1 |
| Guerra, JAO | 2 |
| Piccica, M | 1 |
| Lagi, F | 1 |
| Bartoloni, A | 1 |
| Zammarchi, L | 1 |
| Bourée, P | 2 |
| Soto, P | 2 |
| Ajata, A | 1 |
| Luque, C | 1 |
| Tintaya, C | 1 |
| Paz, D | 2 |
| Rivero, D | 2 |
| Berman, J | 3 |
| Gadelha, EPN | 1 |
| Ramasawmy, R | 1 |
| da Costa Oliveira, B | 1 |
| Morais Rocha, N | 1 |
| Allan Villa Rouco da Silva, G | 1 |
| Gabrielle Ramos de Mesquita, T | 1 |
| Chrusciak Talhari Cortez, C | 1 |
| Chrusciak Talhari, A | 1 |
| Uribe-Restrepo, AF | 1 |
| Prieto, MD | 1 |
| Cossio, A | 1 |
| Desai, MM | 1 |
| Vieira-Gonçalves, R | 1 |
| Fagundes-Silva, GA | 1 |
| Heringer, JF | 1 |
| Fantinatti, M | 1 |
| Da-Cruz, AM | 1 |
| Oliveira-Neto, MP | 1 |
| Gomes-Silva, A | 1 |
| Cavalcanti de Queiroz, A | 1 |
| Alves, MA | 1 |
| Barreiro, EJ | 1 |
| Lima, LM | 1 |
| Alexandre-Moreira, MS | 1 |
| Muñoz, BY | 1 |
| Mantilla, JC | 1 |
| Barros, NB | 1 |
| Migliaccio, V | 1 |
| Facundo, VA | 1 |
| Ciancaglini, P | 1 |
| Stábeli, RG | 1 |
| Nicolete, R | 1 |
| Silva-Jardim, I | 1 |
| Monge-Maillo, B | 1 |
| López-Vélez, R | 1 |
| Inceboz, T | 1 |
| Lambrecht, FY | 1 |
| Eren, MŞ | 1 |
| Girginkardeşler, N | 1 |
| Bekiş, R | 1 |
| Yilmaz, O | 1 |
| Er, Ö | 1 |
| Özbilgin, A | 1 |
| Gomes, CM | 1 |
| Cesetti, MV | 1 |
| de Morais, OO | 1 |
| Mendes, MS | 1 |
| Roselino, AM | 1 |
| Sampaio, RN | 1 |
| Hu, RV | 2 |
| Straetemans, M | 1 |
| Kent, AD | 2 |
| Sabajo, LO | 3 |
| de Vries, HJ | 2 |
| Fat, RF | 2 |
| Mans, DR | 1 |
| Lai A Fat, EJ | 2 |
| Schoone, GJ | 1 |
| Adams, ER | 1 |
| Rood, EJ | 1 |
| Alba, S | 1 |
| Lai A Fat, RF | 2 |
| Schallig, HD | 2 |
| Quispe, J | 1 |
| Toledo, J | 1 |
| Rosypal, AC | 1 |
| Werbovetz, KA | 1 |
| Salem, M | 1 |
| Stephens, CE | 1 |
| Kumar, A | 1 |
| Boykin, DW | 1 |
| Hall, JE | 1 |
| Tidwell, RR | 1 |
| Ronet, C | 1 |
| Darsissac, E | 1 |
| Lise, MC | 1 |
| Marie, DS | 1 |
| Clity, E | 1 |
| Tacchini-Cottier, F | 1 |
| Launois, P | 2 |
| van der Meide, WF | 1 |
| Jensema, AJ | 1 |
| Peekel, I | 1 |
| Faber, WR | 3 |
| Padovese, V | 1 |
| Terranova, M | 1 |
| Toma, L | 1 |
| Barnabas, GA | 1 |
| Morrone, A | 1 |
| García-Lázaro, M | 1 |
| Villar, C | 1 |
| Natera, C | 1 |
| Rivero, A | 1 |
| Dorlo, TP | 1 |
| Kager, PA | 3 |
| Oliveira, LF | 1 |
| Schubach, AO | 1 |
| Martins, MM | 1 |
| Passos, SL | 1 |
| Oliveira, RV | 1 |
| Marzochi, MC | 1 |
| Andrade, CA | 1 |
| Vrede, MA | 1 |
| Soetosenojo, RM | 1 |
| Nacher, M | 4 |
| Carme, B | 6 |
| Clyti, E | 6 |
| Sainte Marie, D | 3 |
| Guibert, P | 3 |
| Pradinaud, R | 9 |
| Delobel, P | 1 |
| Bray, PG | 1 |
| Barrett, MP | 1 |
| Ward, SA | 1 |
| de Koning, HP | 1 |
| Lightburn, E | 1 |
| Morand, JJ | 1 |
| Meynard, JB | 1 |
| Kraemer, P | 1 |
| Chaudier, B | 1 |
| Pages, F | 1 |
| Garnotel, E | 1 |
| Patte, JH | 1 |
| Banzet, S | 2 |
| Dampierre, H | 1 |
| Lepage, J | 1 |
| Morillon, M | 2 |
| Boutin, JP | 1 |
| Hovette, P | 1 |
| Chouc, C | 1 |
| AZULAY, RD | 1 |
| VIVAS, A | 1 |
| AZULAY, E | 1 |
| El Hajj, L | 1 |
| Thellier, M | 1 |
| Carrière, J | 1 |
| Bricaire, F | 1 |
| Danis, M | 1 |
| Caumes, E | 3 |
| Sainte-Marie, D | 4 |
| Dedet, JP | 4 |
| Sobesky, M | 1 |
| Bissuel, F | 1 |
| Del Giudice, P | 1 |
| Zeegelaar, JE | 1 |
| Steketee, WH | 1 |
| van Thiel, PP | 1 |
| Wetsteyn, JC | 1 |
| Andersen, EM | 1 |
| Cruz-Saldarriaga, M | 1 |
| Luz-Cjuno, M | 1 |
| Echevarria, J | 1 |
| Miranda-Verastegui, C | 1 |
| Colina, O | 1 |
| Berman, JD | 2 |
| Piñero, J | 1 |
| Temporal, RM | 1 |
| Silva-Gonçalves, AJ | 1 |
| Jiménez, IA | 1 |
| Bazzocchi, IL | 1 |
| Oliva, A | 1 |
| Perera, A | 1 |
| Leon, LL | 1 |
| Valladares, B | 1 |
| Jauréguiberry, S | 1 |
| Graby, G | 1 |
| Roussel, M | 1 |
| Frémont, G | 1 |
| Rotureau, B | 1 |
| Minodier, P | 1 |
| Parola, P | 1 |
| López-Medrano, F | 1 |
| Costa, JR | 1 |
| Rodriguez-Peralto, JL | 1 |
| Aguado, JM | 1 |
| Antinori, S | 1 |
| Longhi, E | 1 |
| Bestetti, G | 1 |
| Piolini, R | 1 |
| Acquaviva, V | 1 |
| Foschi, A | 1 |
| Trovati, S | 1 |
| Parravicini, C | 1 |
| Corbellino, M | 1 |
| Meroni, L | 1 |
| Tuon, FF | 1 |
| Amato, VS | 1 |
| Graf, ME | 1 |
| Siqueira, AM | 1 |
| Nicodemo, AC | 1 |
| Amato Neto, V | 1 |
| Gangneux, JP | 1 |
| Sauzet, S | 1 |
| Donnard, S | 1 |
| Meyer, N | 1 |
| Cornillet, A | 1 |
| Pratlong, F | 3 |
| Guiguen, C | 1 |
| Buffet, P | 2 |
| Gentilini, M | 1 |
| Blum, J | 1 |
| Hatz, C | 1 |
| Junghanss, T | 1 |
| Belec, L | 1 |
| Grogl, M | 2 |
| Soto-Mancipe, J | 1 |
| Larriviere-Chouc, C | 1 |
| De Pina, JJ | 1 |
| Faraut-Gambarelli, F | 1 |
| Normand, P | 1 |
| Raccurt, CP | 1 |
| Moreau, B | 1 |
| Cotellon, P | 1 |
| Juminer, B | 1 |
| Herrmann, BL | 1 |
| Saller, B | 1 |
| Sauer, J | 1 |
| Brockmeyer, N | 1 |
| Mann, K | 1 |
| Hamerlinck, FF | 1 |
| van Gool, T | 1 |
| Hellier, I | 1 |
| Dereure, O | 1 |
| Tournillac, I | 1 |
| Guillot, B | 1 |
| Guilhou, JJ | 1 |
| Gardon, J | 1 |
| Calza, L | 1 |
| Marinacci, G | 1 |
| Manfredi, R | 1 |
| Colangeli, V | 1 |
| Fortunato, L | 1 |
| Chiodo, F | 1 |
| Lieber-Mbomeyo, A | 1 |
| Lipsker, D | 1 |
| Miléa, M | 1 |
| Heid, E | 1 |
| Mattot, M | 1 |
| Ninane, J | 1 |
| Bigaignon, G | 1 |
| Vermylen, C | 1 |
| Cornu, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study[NCT03096457] | Phase 2/Phase 3 | 80 participants (Actual) | Interventional | 2017-04-15 | Completed | ||
| Efficacy and Safety of Single, Double and Triple Dose Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis: a Pilot Study[NCT02919605] | Phase 2 | 159 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [NCT03009422] | 20 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | |||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
12 reviews available for pentamidine and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Leishmaniasis, | 2021 |
Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cryotherapy; Humans; Immunotherapy; Leishmaniasis, Cutaneous; Leishma | 2013 |
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Drug-Related Side Effects and Adverse Reactions; Hum | 2011 |
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania mexicana; Leishmaniasis, Cutaneou | 2003 |
Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases.
Topics: Adolescent; Adult; Age Distribution; Aged; Animals; Child; Child, Preschool; Female; Humans; Inciden | 2004 |
Cutaneous leishmaniasis treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; | 2007 |
Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Americas; Antiprotozoal Agents; Antiretroviral Therapy, Highly A | 2007 |
Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Developing Countries; Endemic Diseases; Hu | 2008 |
[Treatment of localized cutaneous leishmaniasis].
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Itraconazole; Ketoconazole; | 1994 |
[The therapy of cutaneous and mucocutaneous leishmaniasis].
Topics: Allopurinol; Animals; Antimony; Hot Temperature; Humans; Imidazoles; Leishmania braziliensis; Leishm | 1994 |
Leishmaniasis: report of 33 cases and a review of the literature.
Topics: Allopurinol; Animals; Child, Preschool; Disease Reservoirs; Female; Global Health; Humans; Leishmani | 1993 |
[Leishmania (Viannia) braziliensis Vianna, 1911 in French Guiana. Clinical, therapeutic and epidemiological considerations in the ninth human diagnosed case].
Topics: Adult; Animals; Antiprotozoal Agents; French Guiana; Humans; Leishmania braziliensis; Leishmaniasis, | 1996 |
9 trials available for pentamidine and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Treatment of cutaneous leishmaniasis with a sequential scheme of pentamidine and tamoxifen in an area with a predominance of Leishmania (Viannia) guyanensis: A randomised, non-inferiority clinical trial.
Topics: Antiprotozoal Agents; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneous; Pentamidine; Tamoxife | 2023 |
Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
Topics: Administration, Topical; Adult; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis | 2019 |
An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.
Topics: Adolescent; Adult; Antiprotozoal Agents; Brazil; Dose-Response Relationship, Drug; Drug-Related Side | 2018 |
Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Intention to Treat Analysis; Leishman | 2015 |
Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis.
Topics: Adult; Antimony; Drug Administration Schedule; Female; Humans; Injections, Intralesional; Leishmania | 2016 |
Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Topics: Adult; Animals; Antiprotozoal Agents; Female; Humans; Infusions, Intravenous; Leishmaniasis, Cutaneo | 2005 |
Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine.
Topics: Adult; Cohort Studies; Colombia; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Middle Aged; P | 1994 |
Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Colombia; Follow-Up Studies; Humans; Inj | 1993 |
Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasi | 2000 |
48 other studies available for pentamidine and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects.
Topics: Adult; Antiprotozoal Agents; Disease Outbreaks; Female; French Guiana; Humans; Leishmania; Leishmani | 2021 |
In vitro selection of ketoconazole-pentamidine-resistant Leishmania (Viannia) braziliensis strains.
Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Drug Resistance; Drug Therapy, Combination; Fem | 2022 |
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies.
Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati | 2022 |
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies.
Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati | 2022 |
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies.
Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati | 2022 |
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies.
Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati | 2022 |
Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study.
Topics: Aged; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Cutaneous; Pentamidine; Retrospective Stud | 2023 |
Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of
Topics: Amphotericin B; Combined Modality Therapy; Humans; Leishmaniasis, Cutaneous; Pentamidine; Skin | 2023 |
Using pentamidine to treat cutaneous leishmaniasis in children: a 10-year study in French Guiana.
Topics: Antiprotozoal Agents; Child; Female; French Guiana; Humans; Injections, Intramuscular; Leishmaniasis | 2023 |
Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure.
Topics: Adult; Female; French Guiana; Genetic Variation; Genotyping Techniques; Humans; Leishmania guyanensi | 2021 |
Drug screening using shape-based virtual screening and
Topics: Animals; Antiprotozoal Agents; Benzimidazoles; Cells, Cultured; Disease Models, Animal; Drug Evaluat | 2021 |
Distribution, treatment outcome and genetic diversity of Leishmania species in military personnel from Colombia with cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Colombia; DNA, Protozoan; Genetic Variation; Haplotypes; HSP70 Heat-Shock Prot | 2020 |
Treatment of tegumentary leishmaniasis in two hemodialysis patients with end-stage renal disease using two series of pentamidine.
Topics: Antiprotozoal Agents; Humans; Kidney Failure, Chronic; Leishmaniasis, Cutaneous; Pentamidine; Renal | 2021 |
Leishmaniose cutanée et pentamidine.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Pentamidine | 2017 |
Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimony; Antiprotozoal Agents; Child; Colombia; Cross-S | 2019 |
First report of treatment failure in a patient with cutaneous leishmaniasis infected by Leishmania (Viannia) naiffi carrying Leishmania RNA virus: a fortuitous combination?
Topics: Adult; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Pentamidine; Polymerase Chain Reaction; R | 2019 |
Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis.
Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Caspases; Cell Cycle; Cell Line; Cell Membrane; | 2019 |
Therapeutic response and safety of the topical, sequential use of antiseptic, keratolytic, and pentamidine creams (3-PACK) on Leishmania (Viannia) braziliensis-infected mice.
Topics: Animals; Anti-Infective Agents, Local; Chlorhexidine; Disease Models, Animal; Drug Therapy, Combinat | 2019 |
Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: macrophage as target cell.
Topics: Animals; Antiprotozoal Agents; Combretum; Disease Models, Animal; Interleukin-10; Interleukin-12; Le | 2013 |
Evaluation of (131)I-pentamidine for scintigraphy of experimentally Leishmania tropica-infected hamsters.
Topics: Animals; Disease Models, Animal; Iodine Radioisotopes; Leishmania tropica; Leishmaniasis, Cutaneous; | 2014 |
The influence of treatment on the development of leishmaniasis recidiva cutis: a 17-year case-control study in Midwestern Brazil.
Topics: Adolescent; Adult; Amphotericin B; Brazil; Case-Control Studies; Female; Humans; Incidence; Leishman | 2015 |
Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Female; Humans; Injections, Intramuscular; Leishmania | 2016 |
Inhibition by Dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis.
Topics: Amidines; Animals; Antiprotozoal Agents; Cells, Cultured; Furans; Humans; Inhibitory Concentration 5 | 2008 |
In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Female; Forkhead Transcription Factors; Gene Expre | 2009 |
Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname.
Topics: Adolescent; Adult; Animals; Cohort Studies; Developing Countries; Dose-Response Relationship, Drug; | 2009 |
Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Ethiopia; Female; HIV Infections; | 2009 |
[Raised tattoos in a human-immunodeficiency-virus-infected patient].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral | 2009 |
Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns.
Topics: Antiprotozoal Agents; Ethiopia; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Megl | 2010 |
Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Drug Administration Schedule | 2002 |
Influence of meteorological parameters on the clinical presentation of cutaneous leishmaniasis in French Guiana and on the efficacy of pentamidine treatment of the disease.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Female; French Guiana; Human | 2002 |
Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Creatine Kinase; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; | 2003 |
[Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate].
Topics: Antiprotozoal Agents; France; French Guiana; Humans; Injections, Intramuscular; Leishmaniasis, Cutan | 2003 |
[Case of cutaneous leishmaniasis simulating syphilis (face) and frambesia (lower extremities) successfully treated with a diamidine].
Topics: Amidines; Face; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Lower Extremity; Pentamidine; Syphi | 1953 |
Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions.
Topics: Adult; Animals; Antiprotozoal Agents; Back; Breast; Diagnosis, Differential; Female; Fingers; French | 2004 |
Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Case-Control Studies; CD4 | 2004 |
Changing pattern of imported cutaneous leishmaniasis in the Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimony; Antiprotozoal Agents; Child; Child, Preschool; | 2005 |
New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis.
Topics: Absorbable Implants; Animals; Antiprotozoal Agents; Chalcone; Drug Therapy, Combination; Lactic Acid | 2006 |
Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients.
Topics: Adult; Antiprotozoal Agents; Drug Administration Schedule; Female; Humans; Leishmaniasis, Cutaneous; | 2006 |
Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana.
Topics: Adult; Antiprotozoal Agents; Drug Administration Schedule; Female; French Guiana; Humans; Injections | 2006 |
An HIV-positive man with tattoo induration.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antiprotozoal Agents; Biopsy, Needle | 2007 |
Recurrent American cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Military Personnel; Pentamidine; Recurrence | 2007 |
[Identification of Leishmania (V) guyanensis during recurrences of cutaneous leishmaniasis contracted in French Guyana].
Topics: Animals; Antiprotozoal Agents; French Guiana; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneou | 1996 |
[26-year-old patient with cutaneous leishmaniasis and an initial diabetes mellitus manifestation].
Topics: Adult; Antiprotozoal Agents; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female; Follow | 1999 |
Serum neopterin concentrations during treatment of leishmaniasis: useful as test of cure?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents | 2000 |
[Epidemics of cutaneous leishmaniasis in military personnel working in French Guiana].
Topics: Antiprotozoal Agents; Bedding and Linens; Clothing; French Guiana; Humans; Insect Repellents; Insect | 2000 |
Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Confidence Intervals; French Guiana; Hu | 2001 |
High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Cytokines; Female; Humans; Interleukin-10; | 2001 |
Seasonal fluctuations of incubation, healing delays, and clinical presentation of cutaneous leishmaniasis in French Guiana.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Disease Susceptibility; Female; French Guiana; Hum | 2001 |
Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous | 2001 |
[Rhabdomyolysis induced by pentamidine (Pentacarinat) during treatment of cutaneous leishmaniasis: 2 cases].
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Intramusc | 2002 |
Visceral and cutaneous leishmaniasis in an European paediatric population.
Topics: Animals; Antiprotozoal Agents; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Fema | 1992 |